| Gene |
SOD1 |
| UniProt |
P00441 |
| PDB |
1SPD, 2C9V, 3ECU, 4BCZ |
| Mol. Weight |
16 kDa (monomer), 32 kDa (homodimer) |
| Localization |
Cytoplasm, mitochondrial intermembrane space |
| Family |
Cu/Zn superoxide dismutase family |
| Diseases |
ALS |
Sod1 (Cu Zn Superoxide Dismutase) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Superoxide Dismutase 1 (SOD1) is a 154-amino acid cytosolic and mitochondrial intermembrane space enzyme encoded by the SOD1 gene on chromosome 21q22.11. It is a member of the Cu/Zn superoxide dismutase family and functions as a crucial antioxidant defense enzyme by catalyzing the dismutation of superoxide radical (O₂⁻) into hydrogen peroxide (H₂O₂) and molecular oxygen (O₂). This enzymatic activity protects cells from oxidative stress, which is particularly important in high-energy-demand tissues like neurons and motor neurons.
SOD1 gained profound medical significance when mutations in this gene were identified as the first known cause of familial amyotrophic lateral sclerosis (ALS) in 1993. Since then, over 180 SOD1 mutations have been linked to approximately 15-20% of familial ALS cases, making SOD1 one of the most extensively studied proteins in neurodegenerative disease research. The discovery established that protein misfolding and aggregation could cause ALS, paving the way for understanding other neurodegenerative disorders.
SOD1 is a 154-residue protein with the following structural features:
- β-sheet dominant fold: Eight antiparallel β-strands forming a β-barrel (Greek key topology)
- Disulfide bond: Cys57-Cys146 forms an intramolecular disulfide bond essential for stability
- Metal binding sites: One copper ion (catalytic) and one zinc ion (structural) per subunit
- Dimer interface: Two monomers form a stable homodimer
SOD1 requires copper and zinc ions for full enzymatic activity and structural stability:
Copper site (catalytic):
- Histidine residues (His46, His48, His63, His120) coordinate copper
- Catalyzes superoxide dismutation through redox cycling
- Copper is essential for dismutase activity
Zinc site (structural):
- Histidine residues (His63, His71, His80, His120) coordinate zinc
- Stabilizes the protein structure
- Zinc binding occurs first during maturation
Key structural elements include:
- Greek key β-barrel: The core structural motif
- Loop regions: Dynamic loops that can undergo conformational changes
- Dimerization interface: Hydrophobic interactions between monomers
- Electrostatic channel: Guides substrate (O₂⁻) to active site
SOD1 undergoes several modifications that affect its function:
- Disulfide bond formation: Essential for stability
- Copper/Zinc insertion: Required for activity
- Acetylation: Can affect dimerization
- Oxidation: Can lead to dysfunction
SOD1's primary function is catalyzing the dismutation of superoxide radicals:
2 O₂⁻ + 2 H⁺ → H₂O₂ + O₂
This reaction protects cells from:
- Oxidative damage to DNA, proteins, and lipids
- Mitochondrial dysfunction
- Apoptotic cell death
- Cellular senescence
The reaction occurs through a cyclic redox mechanism where copper alternates between Cu⁺ and Cu²⁺ states.
SOD1 is found in multiple cellular compartments:
- Cytoplasm: Major location, ~70% of cellular SOD1
- Mitochondrial intermembrane space: Imported via TOM/TIM machinery
- Nucleus: Lower concentration
- Extracellular: Minor amounts (secreted SOD1 vs. intracellular)
SOD1 in the mitochondrial intermembrane space protects against mitochondrial oxidative stress. The import involves:
- Targeting signal for mitochondrial localization
- TIM22 import complex
- Disulfide relay system (Erv1/Mia40)
Over 180 pathogenic SOD1 mutations have been identified, representing the first genetic cause of familial ALS discovered. These mutations cluster in:
- Dimer interface: Affect dimerization
- Metal binding sites: Reduce metallation
- β-barrel core: Destabilize folding
- Loop regions: Increase aggregation propensity
Common ALS-causing mutations:
- A4V: Most common in North America (~50% of US cases), aggressive
- G93A: Widely used in mouse models, moderate progression
- G37R: Early onset, slowly progressive
- H46R: Asian population, slower progression
- L126Z: Very aggressive, nonsense mutation
SOD1 mutations cause ALS through toxic gain-of-function mechanisms:
Aggregation:
- Mutant SOD1 misfolds and aggregates
- Forms insoluble inclusions in motor neurons
- Sequesters other proteins
- Disrupts cellular proteostasis
Mitochondrial dysfunction:
- Mutant SOD1 accumulates in mitochondria
- Impairs electron transport chain function
- Increases mitochondrial reactive oxygen species
- Causes mitochondrial fragmentation
Axonal transport defects:
- Disrupts cytoskeletal organization
- Impairs kinesin/dynein function
- Reduces delivery of cargo to synapses
Glial cell dysfunction:
- Affects astrocyte support of motor neurons
- Impairs microglial function
- Disrupts oligodendrocyte support
While gain-of-function is predominant, some loss-of-function contributes:
- Reduced antioxidant capacity
- Increased oxidative stress susceptibility
- Impaired mitochondrial function
SOD1 aggregates can propagate in a prion-like manner:
- Mutant SOD1 can template wild-type SOD1 misfolding
- Extracellular SOD1 aggregates can be internalized
- Spreads between neurons and glia
- Contributes to disease progression
SOD1 was the first gene linked to familial ALS, discovered in 1993 by Rosen et al.. This breakthrough:
- Established that single gene mutations can cause ALS
- Showed protein aggregation as disease mechanism
- Enabled development of animal models
- Pioneered therapeutic targeting approaches
Transgenic mouse models expressing mutant human SOD1 have been instrumental:
- G93A SOD1 mouse: Most widely used, progressive disease
- G37R SOD1 mouse: Slower progression
- SOD1 knockout mice: Mild phenotype, show importance in specific contexts
These models recapitulate key features of human ALS:
- Motor neuron loss
- Muscle denervation
- Glial activation
- Progressive paralysis
- ASO therapy: Tofersen (BIIB057) approved for SOD1-ALS
- CRISPR-Cas9: Gene editing approaches in development
- RNAi: Reducing mutant SOD1 expression
- Gene silencing: Allele-specific approaches
Copper chelators/modulators:
- Copper ATSM (CuATSM)
- Doxycycline + minocycline
Aggregation inhibitors:
- Arimoclomol (HSP co-inducer)
- Small molecule disaggregases
Antioxidants:
- Edaravone (approved for ALS)
- CoQ10 and analogs
- Active vaccination: SOD1-based vaccines
- Passive immunotherapy: Anti-SOD1 antibodies
- Antisense antibodies: Targeting extracellular SOD1
- Autophagy enhancers: Rapamycin, trehalose
- UPS modulators: Enhancing protein clearance
- Molecular chaperones: HSP90, Hsp70 modulators
Approved therapies:
- Tofersen (Qalsody): ASO targeting SOD1, FDA approved 2023
- Edaravone (Radicava): Antioxidant, approved for ALS
In development:
- Copper ATSM: Phase 2/3 trials
- Arimoclomol: Phase 3 trials
- Gene therapy approaches: Multiple programs
- SOD1 gene sequencing for mutations
- Predictive testing for family members
- Genotype-phenotype correlation
- Neurofilament light chain (NfL): Elevated in serum/CSF
- pNfH: phosphorylated neurofilament heavy chain
- SOD1 activity: Reduced in mutation carriers
- MRI shows corticospinal tract degeneration
- PET can detect neuroinflammation
- ALSFRS-R progression rate
- Forced vital capacity (FVC)
- Timed Up and Go test
The study of Sod1 (Cu Zn Superoxide Dismutase) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [SOD1 Gene--TEMP--/genes)--FIX--
- [ALS Superoxide Dismutase Pathway--TEMP--/mechanisms)--FIX--
- [ALS--TEMP--/diseases)--FIX--
- [Oxidative Stress Pathway--TEMP--/mechanisms)--FIX--
- [Mitochondrial Dysfunction--TEMP--/mechanisms)--FIX--